733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy

MLA

Catherine King, et al. “733 Integrative Molecular Profiling of High-Grade Primary Prostate Cancer Identifies Patients with a Biomarker Profile That Favors the Combination of Standard of Care (SOC) Therapy with Immunotherapy.” Regular and Young Investigator Award Abstracts, Nov. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-sitc2020.0733.

APA

Catherine King, Evan Kelemen, Fadi Towfic, Timothy Consedine, Sumit Bhattacharya, Christine Tauras, Harris Bell-Temin, Ryan Powles, Tai Wang, Ashok Dongre, Jimena Trillo-Tinoco, Michaela Bowden, Chensheng Zhou, Andrew Browne, Anne Lewin, David M. Nelson, Christos Hatzis, Ana Lako, Zoe Bleicher, … Kenzie Macisaac. (2020). 733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2020-sitc2020.0733

Chicago

Catherine King, Evan Kelemen, Fadi Towfic, Timothy Consedine, Sumit Bhattacharya, Christine Tauras, Harris Bell-Temin, et al. 2020. “733 Integrative Molecular Profiling of High-Grade Primary Prostate Cancer Identifies Patients with a Biomarker Profile That Favors the Combination of Standard of Care (SOC) Therapy with Immunotherapy.” Regular and Young Investigator Award Abstracts, November. doi:10.1136/jitc-2020-sitc2020.0733.